NCT00617123View on ClinicalTrials.gov

Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)

PHASE3CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

July 1, 2008

Primary Completion Date

October 1, 2010

Study Completion Date

October 1, 2010

Conditions
AtherosclerosisIschemiaMyocardial InfarctionCerebrovascular Accident
Interventions
DRUG

Vorapaxar 2.5 mg

Vorapaxar 2.5 mg oral tablet

DRUG

Placebo

matching placebo oral tablet

Sponsors
All Listed Sponsors
collaborator

The TIMI Study Group

OTHER

collaborator

Duke Clinical Research Institute

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY